Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTE-451 Phase 1 MAD in active plaque psoriasis
NCT03018509Phase 1Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Dec 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JTE-451 in plaque psoriasis (5 arms), sponsored by Akros Pharma Inc. Primary endpoints: Number of adverse events at 4 weeks, Percent change from baseline in the clinical target PLSS at Week 4 and 7 more. Started Dec 2016; status: completed.
02
Drugs
JTE-451
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03018509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018509.